View Structure Therapeutics, Inc. Sponsored ADR GPCR stock quote prices, financial information, real-time forecasts, and company news from CNN.
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
Valuation and recent performance snapshot Structure Therapeutics (GPCR) has drawn attention after recent trading moves, ...
Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor (GPCR) drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a ...
G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers have discovered the vast potential for GPCR-targeting drugs in treating a range of health conditions, ...
Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options begin trading today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is ...
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results